Arm Forecast, price target & analysts
Why the stock moved Beta
Arm Target price 2026 - Analyst rating & recommendation
Arm Classifications & Recommendation
Arm Price Target
| Target Price | $285.60 |
| Price | $228.77 |
| Potential | 24.84% |
| Number of Estimates | 41 |
| 41 Analysts have issued a price target Arm 2027 . The average Arm target price is $285.60. This is 24.84% higher than the current stock price. The highest price target is $504.00 120.31% , the lowest is $126.25 44.81% . | |
| A rating was issued by 45 analysts: 27 Analysts recommend Arm to buy, 16 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Arm stock has an average upside potential 2027 of 24.84% . Most analysts recommend the Arm stock at Purchase. |
Sales and Margin forecast 2027, 2028 to 2033
46 Analysts have issued a sales forecast Arm 2027 . The average Arm sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
30 Analysts have issued an Arm EBITDA forecast 2027. The average Arm EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
45 Arm Analysts have issued a net profit forecast 2027. The average Arm net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2033
Current Arm Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Rosenblatt |
Buy
➜
Buy
|
Unchanged | Jul 31 2026 |
| TD Cowen |
Buy
➜
Buy
|
Unchanged | Jul 30 2026 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 30 2026 |
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Jul 30 2026 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Jul 30 2026 |
| UBS |
Buy
➜
Buy
|
Unchanged | Jul 30 2026 |
| Needham |
Buy
➜
Buy
|
Unchanged | Jul 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Jul 31 2026 |
|
Unchanged
TD Cowen:
Buy
➜
Buy
|
Jul 30 2026 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jul 30 2026 |
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Jul 30 2026 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Jul 30 2026 |
|
Unchanged
UBS:
Buy
➜
Buy
|
Jul 30 2026 |
|
Unchanged
Needham:
Buy
➜
Buy
|
Jul 30 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
